Jorge Nieva, MD - Keck School of ...

Dr. Jorge J. Nieva

Claim this profile

USC / Norris Comprehensive Cancer Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
18 reported clinical trials
27 drugs studied

About Jorge J. Nieva

Education:

  • Earned an MD (Doctor of Medicine) from an unspecified institution.

Experience:

  • Associated with the USC Norris Comprehensive Cancer Center, a part of the Keck School of Medicine at USC.
  • Serves as a medical oncologist, specializing in cancer treatment and research.
  • Engages in a multidisciplinary team approach to enhance patient care, prevention, research, and education in cancer treatment.

Area of expertise

1Lung Cancer
Jorge J. Nieva has run 10 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage II
Stage IV
2Non-Small Cell Lung Cancer
Jorge J. Nieva has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
USC / Norris Comprehensive Cancer Center
Image of trial facility.
Los Angeles County-USC Medical Center

Clinical Trials Jorge J. Nieva is currently running

Image of trial facility.

Tazemetostat + Topotecan + Pembrolizumab

for Small Cell Lung Cancer

This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement (recurrent). Tazemetostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tazemetostat in combination with topotecan and pembrolizumab may shrink or stabilize recurrent small cell lung cancer.
Recruiting1 award Phase 119 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Jorge J. Nieva

Clinical Trial Related5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Jorge J. Nieva has experience with
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Nivolumab
  • Biospecimen Collection
  • Berzosertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jorge J. Nieva specialize in?
Is Jorge J. Nieva currently recruiting for clinical trials?
Are there any treatments that Jorge J. Nieva has studied deeply?
What is the best way to schedule an appointment with Jorge J. Nieva?
What is the office address of Jorge J. Nieva?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security